@article{89f30875196b4333bbe7fe8819dc5a47,
title = "Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis",
abstract = "The NORAM (Nonrenal Wegener's Granulomatosis Treated Alternatively with Methotrexate [MTX]) trial demonstrated that MTX can replace cyclophosphamide (CYC) as remission-inducing treatment for patients with newly diagnosed early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Duration of relapse-free survival was longer among CYC-treated patients than among MTX-treated patients during short-term followup. The aim of the present study was to describe the long-term outcome in patients enrolled in the randomized clinical trial.",
keywords = "Adolescent, Adult, Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Cyclophosphamide, Disease Progression, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Questionnaires, Remission Induction, Treatment Outcome",
author = "Mikkel Faurschou and Kerstin Westman and Niels Rasmussen and {de Groot}, Kirsten and Oliver Flossmann and Peter H{\"o}glund and Jayne, {David R W} and {European Vasculitis Study Group}",
note = "Copyright {\textcopyright} 2012 by the American College of Rheumatology.",
year = "2012",
doi = "10.1002/art.34547",
language = "English",
volume = "64",
pages = "3472--7",
journal = "Arthritis & Rheumatism",
issn = "0004-3591",
publisher = "John Wiley & Sons Inc.",
number = "10",
}